42 results
424B5
DYN
Dyne Therapeutics, Inc.
22 May 24
Prospectus supplement for primary offering
4:30pm
) on the net gain derived from the taxable disposition, which may be offset by certain U.S. source capital losses of the non-U.S. holder, if any; or we
424B5
DYN
Dyne Therapeutics, Inc.
20 May 24
Prospectus supplement for primary offering
4:24pm
may be offset by certain U.S. source capital losses of the non-U.S. holder, if any; or we are, or have been, at any time during the five-year period
424B5
lhxe27b l80yopv
5 Jan 24
Prospectus supplement for primary offering
4:07pm
424B5
bpylh0lu
3 Jan 24
Prospectus supplement for primary offering
4:37pm